Xi Chen, Meiying Yan, Rujing Sun, Biao Kan, Fenxia Fan
{"title":"The characteristics and genomic analysis of Vibrio cholerae phage VP1","authors":"Xi Chen, Meiying Yan, Rujing Sun, Biao Kan, Fenxia Fan","doi":"10.1016/j.virol.2025.110673","DOIUrl":null,"url":null,"abstract":"<div><div>The lytic bacteriophage VP1 specifically targets <em>Vibrio cholerae</em> (<em>V. cholerae</em>), showing excellent therapeutic potential. It features a 55-min latency period, large burst size (255 virions/cell), and remarkable stability (pH 5–12). Genomic sequencing revealed a double-stranded DNA genome of 42,845 bp with a G + C content of 45.49 %. Among the 61 predicted open reading frames (ORFs), 55 were validated by proteomic analysis, while only 16 exhibited functional homology to known proteins in public databases. The genome lacks tRNA genes, CRISPR-associated elements, virulence factors, or antibiotic resistance genes, underscoring its safety profile. It effectively lyses O1 and O139 <em>V. cholerae</em> strains while showing no activity against other <em>Vibrio</em> species. Comparative genomic analysis showed VP1 shares limited similarity (<71.39 % identity) with five <em>Vibrio</em> phages. Phylogenetic analysis of terminase large subunit (TerL) and major capsid protein (MCP) genes further confirmed VP1's distinct evolutionary position, clustering with <em>V. splendidus</em> phage but forming a separate clade from established <em>Caudovirales</em> families. Given its potent lytic activity, genomic stability, unique phylogenetic position, and absence of harmful genetic elements, VP1 represents a putative novel phage lineage within <em>Podovirales</em>.</div></div>","PeriodicalId":23666,"journal":{"name":"Virology","volume":"612 ","pages":"Article 110673"},"PeriodicalIF":2.4000,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0042682225002879","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The lytic bacteriophage VP1 specifically targets Vibrio cholerae (V. cholerae), showing excellent therapeutic potential. It features a 55-min latency period, large burst size (255 virions/cell), and remarkable stability (pH 5–12). Genomic sequencing revealed a double-stranded DNA genome of 42,845 bp with a G + C content of 45.49 %. Among the 61 predicted open reading frames (ORFs), 55 were validated by proteomic analysis, while only 16 exhibited functional homology to known proteins in public databases. The genome lacks tRNA genes, CRISPR-associated elements, virulence factors, or antibiotic resistance genes, underscoring its safety profile. It effectively lyses O1 and O139 V. cholerae strains while showing no activity against other Vibrio species. Comparative genomic analysis showed VP1 shares limited similarity (<71.39 % identity) with five Vibrio phages. Phylogenetic analysis of terminase large subunit (TerL) and major capsid protein (MCP) genes further confirmed VP1's distinct evolutionary position, clustering with V. splendidus phage but forming a separate clade from established Caudovirales families. Given its potent lytic activity, genomic stability, unique phylogenetic position, and absence of harmful genetic elements, VP1 represents a putative novel phage lineage within Podovirales.
期刊介绍:
Launched in 1955, Virology is a broad and inclusive journal that welcomes submissions on all aspects of virology including plant, animal, microbial and human viruses. The journal publishes basic research as well as pre-clinical and clinical studies of vaccines, anti-viral drugs and their development, anti-viral therapies, and computational studies of virus infections. Any submission that is of broad interest to the community of virologists/vaccinologists and reporting scientifically accurate and valuable research will be considered for publication, including negative findings and multidisciplinary work.Virology is open to reviews, research manuscripts, short communication, registered reports as well as follow-up manuscripts.